# David Hallal

> David L. Hallal is a biotechnology executive and co-founder of ElevateBio, where he serves as executive chairman after leading the company as chairman and CEO. He is also chairman and CEO of Scholar Rock. A University of New Hampshire psychology graduate, he previously built commercial operations at Alexion and served as its CEO from 2015 to 2016.

- **Role:** Executive Chairman at ElevateBio; Chairman and Chief Executive Officer at Scholar Rock
- **Organizations:** ElevateBio, Scholar Rock, Alexion Pharmaceuticals, Amgen, Biogen, OSI Eyetech, Upjohn, Seer, Kalaris Therapeutics, MPM Capital
- **Education:** B.A. in Psychology, University of New Hampshire
- **Known for:** Co-founded ElevateBio and led it as chairman and CEO for nearly eight years., Built and led commercial infrastructure during Alexion’s expansion to a 50-country operating platform., Served in executive leadership at Alexion during growth from a pre-commercial company to more than $3 billion in annual revenue by 2016.

## Career timeline

- **1988** — Graduated from the University of New Hampshire with a B.A. in Psychology.
- **2006** — Joined Alexion in June to build and lead U.S. commercial operations.
- **2014** — Became Alexion chief operating officer and joined its board in September.
- **2015** — Became Alexion CEO on April 1, succeeding Leonard Bell.
- **2016** — Left Alexion in December; the company stated personal reasons for his resignation, announced during an internal sales-practices investigation.
- **2017** — Co-founded ElevateBio with Mitchell Finer and Vikas Sinha; became chairman of Scholar Rock.
- **2019** — ElevateBio publicly launched in May with $150 million in Series A financing.
- **2021** — ElevateBio BaseCamp received the ISPE Facility of the Year category award for Operational Excellence.
- **2023** — ElevateBio announced $401 million in Series D financing.
- **2025** — Appointed Scholar Rock CEO on April 28 and announced transition to ElevateBio executive chairman.
- **2026** — Continued as ElevateBio executive chairman as Christopher Murphy became CEO in January; remained Scholar Rock chairman and CEO in October.

## Achievements

- Co-founded ElevateBio and led it as chairman and CEO for nearly eight years.
- Built and led commercial infrastructure during Alexion’s expansion to a 50-country operating platform.
- Served in executive leadership at Alexion during growth from a pre-commercial company to more than $3 billion in annual revenue by 2016.
- Led ElevateBio during the development of BaseCamp, recipient of the 2021 ISPE Operational Excellence category award.

## Latest updates

- **2026-10** — An October 8 Scholar Rock announcement identifies Hallal as chairman and CEO.
- **2026-01** — ElevateBio appointed Christopher Murphy CEO on January 5, with Hallal continuing as executive chairman.
- **2026-01** — ElevateBio reported a sixth consecutive year of revenue growth and a 98% manufacturing batch success rate in its January 8 business update.
- **2025-04** — Became Scholar Rock CEO and announced transition to ElevateBio executive chairman.

## Links

- Website: https://elevate.bio/eb-team/david-hallal/
- LinkedIn: https://www.linkedin.com/in/david-hallal-15a407116/

---

Profile page: https://yespress.io/david-hallal
Published by YesPress — https://yespress.io
Last updated: 2026-10-23